The Client
A global pharmaceutical company traditionally focused in the generic and specialty market is planning to build a rare disease franchise and is looking to acquire a set of assets as the foundation for this franchise.
Challenge
Client needs a commercial and clinical due diligence to evaluate the attractiveness of an AATD asset as a potential cornerstone of its new rare disease franchise.
Our Approach
1. KOL recruitment for PMR:
Recruited 16 pulmonologists treating an average of 73 AATD patients in the last year as well as 6 experts from national (20M-50M lives covered) payer organizations to conduct 60-minute qualitative interviews.
2. TPP-Guided Interview Campaign for Revenue Model Input:
Gathered insights on physician anticipated utilization of target asset in AATD under different market scenarios, including approval of potential gene therapy. Payers were also guided with TPPs to assess pricing potential, potential access barriers, etc.
3. Synthesis of revenue forecast:
Incorporated input from HCPs and payers to develop dynamic revenue model for client to assess AATD market under various future competitive market scenarios
Impact
Catalyzed the creation of a new rare disease franchise by providing dynamic, HCP / payer insight-driven revenue forecast for the future US AATD market, enabling assessment of the opportunity size for a target clinical-stage asset
Example Deliverables
“How to Win in AATD”
Quantitatively-Derived Revenue Forecast
Market Access Success Factors
